Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMINENT trial of pemafibrate for cardiovascular event reduction in high-risk patients with type 2 diabetes
MOH_2017-06-13_000241Phase 3Not yet recruiting
- Sponsor
- Kowa Research Institute
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity comparing pemafibrate with Placebo comparator (2 arms). Primary endpoint: Primary composite cardiovascular endpoint. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
pemafibrate
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on MOH_2017-06-13_000241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-13_000241.